Zhabina A.,Federal State Budgetary Institution Scientific research |
Shikhliarovaa A.,Federal State Budgetary Institution Scientific research |
Gudtskovaa T.,Federal State Budgetary Institution Scientific research |
Braginaa M.,Federal State Budgetary Institution Scientific research |
And 5 more authors.
European Journal of Cancer, Supplement
Background: To evaluate the expression of markers of sensitivity to chemotherapy in patients various solid tumors. Materials and methods: The work includes paraffin blocks NSCLC patients (n = 486); CRC (n = 262); Breast cancer (n = 55); cervical cancer (n = 19); kidney (n = 35); squamous head and neck cancer (n = 15); stomach (n = 51); ovarian (n = 25); melanoma (n = 58); soft tissue sarcomas (n = 52). On our panel discussed the spectrum of expression of enzymes DPD, TP, TS, ERCC1, β-tubulin. Measurement of the expression of these genes produced by polymerase chain reaction in real time according to the method developed at the Institute of Oncology. NN Petrova. Results: The combination of markers of sensitivity to fluoropyrimidine (low levels of DPD, TS, and low/high TP) was observed in patients with NSCLC in 30.9%, 41.9% in colorectal cancer, breast cancer in 31.1%, renal cell carcinona 41.1%, head and neck carcinoma in 14.3%, of gastric cancer in 42.5% melanoma in 39.5% of cases. Marker sensitivity to platinum drugs (low ERCC1) occurs in patients with NSCLC in 68.8%, 57.1% in colorectal cancer, breast cancer in 55.0%, renal cancer in 70.8% of squamous cell carcinoma of the head and neck 50, 0% of gastric cancer in 87.9% in melanoma 63.6% of cases. Marker, is an indirect measure of sensitivity to taxane drugs (low β-tubulin) in patients with NSCLC diagnosed in 72.7% of cases, in 75% of colorectal cancer, breast cancer in 66.7%, renal cancer in 92.3% of gastric cancer to 86.6%, melanoma in 73.5%. Conclusion: The expression of markers in tumor tissue is heterogeneous. Significant heterogeneity of expression of predictive marker indicates on one hand the futility of the empirical approach to the choice of therapy, and on the other the need for their determination in all patients. Information about the molecular and genetic features of the tumor can afford to individualize the choice of drug. Objective data about the informativeness of molecular genetic markers can be obtained on the basis of randomized clinical trials. © 2015. Source